logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table HSR-10. Estimation of the total number of clients in treatment in 2011 or latest available year

CountryYearAll opioid substitution treatment clientsYear All treatment demand clients (TDI)YearTotal number of clients in treatment (ST24)Estimation of total number of clients in treatmentTotal adult population (15-64 yrs) in 2011
Belgium(i)201117 70120115946::17 7017 250 159
Bulgaria(ii)20113 4522011249020114 800(1)48005 033 849
Czech Republic(ii)20115 20020119284200916343(2)163437 327 997
Denmark(ii)20117 60020115686201011119111193 631 760
Germany(ii)201176 2002011755322010164804(3)16480453 966 108
Estonia(ii)20111 076201153220111 222(4)1222906 372
Ireland(ii)20118 72920108511201017238(5)172383 070 462
Greece(ii)20116 7832010583420119 721(6)97217 505 316
Spain(ii)201082 3722011535082011185 896(7)18589631 310 040
France(i)2010145 0002011475192011233 000(8)233 00042 094 161
Italy(ii)2011109 9872011575772010176430(9)17643039 811 683
Cyprus(ii)2011188201199520111 057(10)1057591 923
Latvia(iii)201127720112010::2 0101 398 922
Lithuania(i)2011798::::7982 052 863
Luxembourg(i)20111 2282011224::1 228350 713
Hungary(ii)20116392011478320096 917(11)69176 857 377
Malta(iii)20111 10720111862::1 862289 070
Netherlands(ii)201010 08520111310920103594335 94311 153 778
Austria(ii)201116 78220114563201118 865(12)18 8655 689 364
Poland(ii)20112 20020101342201011341(13)11 34127 483 691
Portugal(ii)201126 35120114388201037983(14)37 9836 981 395
Romania(ii)20117422011185320102163(15)2 16314 988 909
Slovenia(i)20113 557201152120103332(16)3 5571 420 392
Slovakia(iii)201150020112313::2 3133 882 442
Finland(i)20112 00020111443::2 0003 546 558
Sweden(iii)20073 11520116231::6 2316 113 365
UK- England2010/11153 0332010/11219 986
UK-Scotland200722 224::
UK-Northern Irel.2010/1160720122805
UK- Wales2010/112 1292010/1113 284
United Kingdom(ii)177 99320111196522010/12236 075(17)236 07541,642,400
Croatia(iii)20114 0742011766520117 6657 6653 256 353
Turkey(i)20118 07420112117::8 0742 973 387
Norway(iii)20116 64020118817::8 81749 516 670
 

Notes:

Where data are not available for a country, the table entry is left empty.

(i) indicates that the clients considered to calculate the total estimation have been the substitution clients.

(ii) indicates that the clients considered to calculate the total estimation have been the total number of clients in treatment (ST24).

(iii) indicates that the clients considered to calculate the total estimation have been the all treatment demand clients (TDI).

See the data on number of clients in substitution treatment in Table HSR-3 part (i) .

See treatment demand data in Table TDI-2 part (ii) .

(1) Clients who have been in treatment because of opioid problem use (4200), cocaine or amphetamine problem use (200), including an estimate of the number of treated persons for hallucinogens, sedatives or cannabis (400).

(2) The information refers to all clients treated in 2009 for problems with illegal substances in outpatient healthcare facilities (2010 National Report; table 5-3: Number of clinics and number of addictive substance users treated in 2000-2009 (Nechanská et al. 2010; Institute of Health Information and Statistics, 2010a). This figure is an under-estimate as it only refers to clients being treated within these types of facilities and not all available treatment providers in the Czech Republic.

(3) No control for double-counting beyond centre level, estimates based on selected types of specialised treatment centres and extrapolated based on coverage estimates. Outpatient calculation based on 54.385 clients (no individual data, based on 'last episode in a given year in a given centre' related to opiate-related disorders (F11.x), all treatments); inpatient calculation based on clients having ended a treatment episode in a given year (probability to have more than one inpatient episode per year is very low). Additional information: 31.496 hospital treatments due to F11 (in 2009), unclear overlap with specialised treatment centres (estimates based on data from specialised outpatient treatment: 12.6-16.2% parallel treatment in/ discharge to hospitals). Additional source of information based on national substitution register: 77.400 registered clients in substitution treatment (data from specialised treatment centres: For 34.6% of clients treated in outpatient centres and 3.2% of inpatient clients a paral

(4) In addition of clients in opioid substitution treatment, this number consist of 46 clients in Wismari hospital in detoxification treatment and 100 clients in the Tallinn Children's Hospital in detoxification treatment.

(5) The information refers to all clients treated in 2010. Each case (episode) sought treatment for problem (illicit)drug use (excluding those who reported alcohol, hypnotic or sedatives as their main problem drug). The cases include those who reported one of the following as their main problem drug: an opiate, cocaine, a stimulant, hallucinogens, volatile inhalants and cannabis.

(6) The above data come from 86 officially recognized centres which offered treatment services in 2011 and delivered relevant data. They consist of 39 drug-free treatment programmes (2,264 clients), 39 substitution treatment units (6,783 clients), 7 drug-free treatment programmes in prison (394 clients) and 1 outpatient detoxification programme (280 clients). The data collection is based on the 'Treatment Questionnaire' (2010), which is a revised version of the 'Treatment Unit Form/TUF A'. The collected information is controlled annually to check internal consistency. The figure does not include readmissions within the year in the same unit; whereas clearance for double entries among different units is not feasible.

(7) The data refers to clients in treatment for problem heroin use, problem cocaine use, problem amphetamine use, and problem cannabis use. Source: Government Delegation for the National Plan on Drugs.

(8) Number of clients with a prescription of opioid substitution treatment + number illicit drug users seen in specialised centres (CSAPA) but not in opioid substitution treatment. Missing cases : illicit drug users treated in hospitals (outside specialised centres located within hospitals).

(9) Data refers to clients of the public drug outpatient treatment services (Ser.T.) in the year 2010.The total number of individual clients refers to clients who received treatment by Ser.T. for their drug problem. The clients can be treated in Ser.T. (outpatient service), in therapeutic communities (inpatient service) or in prison. The total number of treatment episodes refers to pharmacologically and/or psychosocial treatment performed by Ser.T. for clients who have drug problems. The clients can be treated in Ser.T. (outpatient service), in therapeutic communities (inpatient service) or in prison.

(10) The total number of persons in treatment in 2011 is controlled for double counts (clients entering treatment in the reporting year and those in treatment during the reporting year who had continued treatment from the previous year/s).

(11) Data refers to opiates, amphetamines and cocaine users in treatment in 2009.

'(12) The estimate of the total number of clients in treatment is based on the following considerations and refers to problem opioid users in treatment. a) All outpatient clients in DOKLI with primary drug opiates (treatment prevalence) in 2011: 4216 b) All inpatient clients in DOKLI with primary drug opiates (treatment prevalence) in 2011: 1231c) Coverage of DOKLI outpatient: 93% d) Coverage of DOKLI inpatient: 85% e) Estimate for double counting in DOKLI based on data for Vienna: 21,7% f) Total clients in substitution treatment database in 2011: 16782 g) Estimation for overlap of DOKLI and substitution treatment database based on the DOKLI question 'do you already receive substitution treatment' for clients with primary drug opiates: outpatient: 56,7% inpatient 54,3% Problems and limitations: c + d) the coverage is roughly estimated based on the percentage of treatment facilities delivering data to DOKLI e) the estimate is based on data from Vienna - maybe it is an overestimation for rural areas f) This

(13) Data come from the reporting system conducted by Institute of Psychiatry and Neurology covering only residential treatment due to mental and behavioural disorders caused by using illicit drugs. The residential system of statistical reporting is based on individual statistical questionnaires. Each questionnaire is coded. It is possible to eliminate double counting of persons who enter treatment several times a year, sometimes in many facilities.

(14) Individuals within at least one treatment episode during the reporting year. Includes: Opiates, Cocaine, stimulants, hypnotics and sedatives, hallucinogens, volatile and cannabis.

(15) Data sources: treatment centres under coordination of Ministry of Health, NAA, private centres and prisons. However not all centres (which are under coordination of Ministry of Health) have reported.

(16) Data source: TDI database.

(17) Data refer to England, Northern Ireland and Wales

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Standard Tables 24 (ST24) on 'treatment availability' submitted by NFPs.

Standard Table 34 (TDI): Characteristics of individuals starting treatment for drugs by type of treatment centre submitted by NFPs.

Reitox National Reports.

Eurostat for the demographic data.

Page last updated: Friday, 26 April 2013